5 7

Cited 0 times in

Cited 0 times in

Romosozumab Enhances Implant Stability in Glucocorticoid-Induced Osteoporotic Bone: A Rabbit Model Study

Authors
 Kwon, Ji-won  ;  Moon, Seong-hwan  ;  Suk, Kyung-soo  ;  Park, Si-young  ;  Kim, Hak-sun  ;  Park, Sub-ri  ;  Kim, Namhoo  ;  Lee, Byungho 
Citation
 Neurospine, Vol.22(4) : 880-890, 2025-12 
Journal Title
NEUROSPINE
ISSN
 2586-6583 
Issue Date
2025-12
Keywords
Glucocorticoid ; Implant ; Osteoporosis ; Rabbit ; Romosozumab
Abstract
Objective: Implant fixation in osteoporotic bone presents substantial challenges due to reduced bone mass and compromised microarchitecture. This study investigated whether romosozumab, a sclerostin inhibitor, improves osseointegration and mechanical stability of cancellous bone screws in glucocorticoid-induced osteoporosis. Methods: Fifty-five New Zealand white rabbits were enrolled. Osteoporosis was induced via either bilateral ovariectomy or weekly intramuscular glucocorticoid injections (4–8 mg/kg). Based on bone mineral density results, glucocorticoid injection was selected for experimental induction. Rabbits were divided into 5 groups: control, untreated osteoporosis, parathyroid hormone (PTH), PTH combined with denosumab, and romosozumab. Cancellous bone screws (4.0-mm diameter, titanium alloy) were bilaterally inserted into the iliac bones. Antiosteoporosis treatments were administered for 3-week postimplantation. Histomor-phometric evaluation of bone-to-implant contact (BIC) and bone area fraction occupancy (BAFO) was performed using nondecalcified sectioning and Goldner trichrome staining. Biomechanical pull-out testing measured resistance at 1-mm displacement using a standardized setup on the MTS system. Results: The romosozumab-treated group exhibited superior outcomes. BIC reached 21.2% ± 18.1%, and BAFO was 56.9% ± 9.9%. Pull-out strength significantly increased to 275 ± 55 N in the romosozumab group, outperforming PTH (184 ± 61 N), PTH+denosumab (202 ± 23 N), and untreated osteoporosis (120 ± 33 N). Enhanced collagen structure and neobone formation were observed histologically around implants. Conclusion: Romosozumab significantly enhances cancellous bone screw fixation strength and osseointegration in glucocorticoid-induced osteoporotic bone. These findings suggest its clinical potential as an adjuvant therapy in improving spinal implant outcomes in osteoporotic patients. © 2025 by the Korean Spinal Neurosurgery Society.
Files in This Item:
91452.pdf Download
DOI
10.14245/ns.2550774.387
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Orthopedic Surgery (정형외과학교실) > 1. Journal Papers
Yonsei Authors
Kwon, Ji-Won(권지원) ORCID logo https://orcid.org/0000-0003-4880-5310
Kim, Nam-Hoo(김남후)
Kim, Hak Sun(김학선) ORCID logo https://orcid.org/0000-0002-8330-4688
Moon, Seong Hwan(문성환)
Park, Sub-Ri(박섭리) ORCID logo https://orcid.org/0000-0001-8869-9810
Park, Si Young(박시영)
Suk, Kyung Soo(석경수) ORCID logo https://orcid.org/0000-0003-0633-2658
Lee, Byung Ho(이병호) ORCID logo https://orcid.org/0000-0001-7235-4981
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/210438
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links